The expectation that genomics would result in new therapeutic interventions for infectious
diseases remains unfulfilled. In the post‐genomic era, the decade immediately following the …

The recent years have witnessed significant progress in the development of new drug
candidates for the treatment of TB. While many of these are now in clinical trials, continued …

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium
tuberculosis. Despite decades of research driving advancements in drug development and …

In this Miniperspective we broadly cover the recent developments and strategies that are
being adopted globally in the battle to urgently discover and develop new drugs to treat …

Despite the availability of the BCG vaccine and chemotherapy, tuberculosis (TB) remains a
leading infectious killer worldwide. The recent rise of TB and especially the alarming …

The recent past has experienced a renaissance in tuberculosis (TB) research. New
molecular biology reagents and genetic tools have been developed and whole genome …

Latent tuberculosis infection (LTBI) represents a subclinical, asymptomatic mycobacterial
state affecting approximately 25% of the global population. The substantial prevalence of …

The emergence of drug resistance continues to afflict TB control where drug resistant strains
have become a global health concern. Contrary to drug-sensitive TB, the treatment of …

More than two decades have elapsed since the publication of the first genome sequence of
Mycobacterium tuberculosis (Mtb) which, shortly thereafter, enabled methods to determine …

Every minute, somewhere in the world four people die from tuberculosis (TB), yet it has been
nearly 40 years since a novel drug was introduced to treat this disease. The ever increasing …